Evidence map›Paper›PMID 36928219›Full record

ReviewNature reviews. Disease primers2023

Intracerebral haemorrhage.

Laurent Puy, Adrian R Parry-Jones, Else Charlotte Sandset, Dar Dowlatshahi, Wendy Ziai, Charlotte Cordonnier

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Disease primers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06862388 (Clinical Research on Umbilical Cord Mesenchymal Stem Cells Therapy for Patients With Subacute Intracerebral Hemorrhage), which is not on this map. Cited by 189 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
189citing papers in PubMed, 8 pooled it
54.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06862388 phase1 / phase2not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Clinical Research on Umbilical Cord Mesenchymal Stem Cells Therapy for Patients With Subacute Intracerebral Hemorrhage

TypeinterventionalSponsorTang ZhoupingRan2025 to 2027Enrolled39ConditionsIntracerebral Hemorrhage, Mesenchymal Stem CellArmsDevice: Phase Ⅰ Dose Level 1, Device: Phase Ⅰ Dose Level 2, Device: Phase Ⅰ Dose Level 3, Device: Phase II MTD in Phase I, Device: Phase II lower than the MTD in Phase I
3 · Its place in the literature

Who cites it

189 citing papers in PubMed, 8 syntheses or guidelines pooled it, 264 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Review
  20. Review

129 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 5 countries.

Laurent PuyLille Neuroscience & Cognition (LilNCog) - U1172, University of Lille, Inserm, CHU Lille, Lille, France.
Adrian R Parry-JonesGeoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, Northern Care Alliance NHS Foundation Trust & University of Manchester, Manchester, UK.ORCID 0000-0002-4462-3846
Else Charlotte SandsetDepartment of Neurology, Stroke Unit, Oslo University Hospital, Oslo, Norway.
Dar DowlatshahiDepartment of Medicine (Neurology), University of Ottawa and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Wendy ZiaiDivision of Neurocritical Care, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Charlotte CordonnierLille Neuroscience & Cognition (LilNCog) - U1172, University of Lille, Inserm, CHU Lille, Lille, France. charlotte.cordonnier@univ-lille.fr.
Inserm · FRJohns Hopkins University · USManchester Academic Health Science Centre · GBOslo University Hospital · NOUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intracerebral haemorrhage (ICH) is a dramatic condition caused by the rupture of a cerebral vessel and the entry of blood into the brain parenchyma. ICH is a major contributor to stroke-related mortality and dependency: only half of patients survive for 1 year after ICH, and patients who survive have sequelae that affect their quality of life. The incidence of ICH has increased in the past few decades with shifts in the underlying vessel disease over time as vascular prevention has improved and use of antithrombotic agents has increased. The pathophysiology of ICH is complex and encompasses mechanical mass effect, haematoma expansion and secondary injury. Identifying the causes of ICH and predicting the vital and functional outcome of patients and their long-term vascular risk have improved in the past decade; however, no specific treatment is available for ICH. ICH remains a medical emergency, with prevention of haematoma expansion as the key therapeutic target. After discharge, secondary prevention and management of vascular risk factors in patients remains challenging and is based on an individual benefit-risk balance evaluation.

Indexed as

Quality of LifeStrokeBrainCerebral HemorrhageHematomaHumans

Identifiers

PMID36928219
OpenAlexW4327679563

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.